Journal of Digestive Diseases

Publisher: Chinese Society of Gastroenterology, Blackwell Publishing

Description

  • Impact factor
    1.85
  • 5-year impact
    1.81
  • Cited half-life
    2.80
  • Immediacy index
    0.28
  • Eigenfactor
    0.00
  • Article influence
    0.49
  • Other titles
    Journal of digestive diseases (Online)
  • ISSN
    1751-2980
  • OCLC
    123124871
  • Material type
    Document, Periodical, Internet resource
  • Document type
    Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Blackwell Publishing

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • Some journals impose embargoes typically of 6 or 12 months, occasionally of 24 months
    • no listing of affected journals available as yet
  • Conditions
    • See Wiley-Blackwell entry for articles after February 2007
    • Publisher's version/PDF cannot be used
    • On author's server, institutional server or subject-based server
    • Server must be non-commercial
    • Publisher copyright and source must be acknowledged with set statement ("The definitive version is available at www.blackwell-synergy.com")
    • Articles in some journals can be made Open Access on payment of additional charge
    • 'Blackwell Publishing' is an imprint of 'Wiley'
  • Classification
    ​ yellow

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: IL-35, a recently identified cytokine of IL-12 family, is a potent immunosuppressive cytokine secreted by regulatory T cells (Treg cells) and the newly reported regulatory B cells (Breg cells), which function as a crucial immunosuppressive factor in immune-mediated diseases. The predominant mechanism of suppression associated with the activity of IL-35 is its ability to suppress T-cell proliferation and effector functions. The pathogenic processes of the non-cytopathic hepatitis B virus (HBV) infection related liver diseases are immune-mediated including liver damage and viral control. It has been found that IL-35 is detectable in peripheral CD4(+) T cells in chronic HBV infected patients, whereas it is undetectable in healthy individuals. There is growing evidence that cytokine-mediated immune responses play a pivotal role in determining the clinical outcome during HBV infection. It will be particularly important to investigate the effects of IL-35 in the immunopathogenesis of chronic HBV infection. In this review, the recently understanding of this issue will be discussed. This article is protected by copyright. All rights reserved.
    Journal of Digestive Diseases 12/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: AimWe examined the efficacy and tolerability of hepatic arterial infusion chemotherapy (HAIC) using cisplatin as an alternative option to sorafenib for the treatment of hepatocellular carcinoma (HCC) patients who had not responded to transarterial chemoembolization (TACE).Methods We investigated the medical records of 127 consecutive HCC patients without extrahepatic metastasis (cisplatin, n = 44; sorafenib, n = 83) who had not responded to prior TACE at four institutions. An inverse probability of treatment weighting using propensity scoring was used to adjust for selection biases.ResultsSerious adverse events accounting for treatment discontinuation occurred in 2.3% of the patients in the cisplatin group and 32.5% of those in the sorafenib group. The median overall survival (OS) period was 11.2 months (95% confidence interval [CI]: 4.8–17.7) in the cisplatin group and 10.2 months (95% CI: 8.8–11.5) in the sorafenib group, respectively. After an inverse probability of treatment weighting adjustment, the survival outcome of the HAIC treatment group was not inferior to that of the sorafenib treatment group (hazard ratio, 0.758; 95% CI, 0.471–1.219; P = 0.253).ConclusionHAIC using cisplatin may be an alternative treatment option in select HCC patients who have not responded to prior TACE and cannot tolerate sorafenib.
    Journal of Digestive Diseases 12/2014;
  • Suck Chei Choi, Duowu Zou, Mei Yun Ke, Somchai Leelakusolvong, Jan Tack, Eamonn M M Quigley, Andy Liu, JinYong Kim
    [Show abstract] [Hide abstract]
    ABSTRACT: AimTo evaluate the efficacy of prucalopride (2 mg/day), a novel selective high-affinity 5-hydroxytryptamine type-4 receptor agonist, in relieving chronic constipation-associated symptoms in Asians and non-Asians.Methods This integrated analysis included pooled data from 4 phase-III, multicenter, randomized, double-blind, placebo-controlled studies (NCT00488137, NCT00483886, NCT00485940, NCT01116206) of patients treated with prucalopride 2 mg and placebo. Efficacy in relieving chronic constipation-associated symptoms was evaluated based on improvements in the ‘Patient Assessment of Constipation Symptoms’ scores. Change from baseline in each symptom score was analyzed using an analysis of covariance model, with treatment, study, and baseline spontaneous bowel movement frequency as factors, and baseline value for each symptom score as covariates for each subgroup of interest: Asian and non-Asian.ResultsOverall, 1782 patients (26.7% Asians; 73.3% non-Asians), predominantly women (89.3%), were included. Prucalopride significantly improved bloating, hard stool, and straining (P<0.001, for all), compared with placebo (mean [standard deviation]) in Asians (bloating: −0.5 [0.73], −0.3 [0.73]; hard stool: −0.5 [0.82], −0.2 [0.77]; straining: −0.6 [0.78], −0.4 [0.75]) and non-Asians (bloating: −0.4 [0.71], −0.2 [0.67]; hard stool: −0.3 [0.78], −0.2 [0.79]; straining: −0.3 [0.71], −0.2 [0.69]) irrespective of symptom severity. However, abdominal pain was not significantly relieved in Asians (P=0.103) compared with non-Asians (P<0.001). The most common treatment-emergent adverse events were headache, nausea, diarrhea, and abdominal pain.Conclusions Prucalopride 2 mg/day was found to be well-tolerated and efficacious in relieving all chronic constipation-associated symptoms in both Asians and non-Asians, except for abdominal pain in Asians, over 12 weeks, regardless of their severity.
    Journal of Digestive Diseases 12/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective This study aimed to identify the risk factors associated with rebleeding and to investigate the long-term outcomes after capsule endoscopy (CE) for obscure gastrointestinal bleeding (OGIB) in a large-scale follow-up study.MethodsA retrospective study was conducted in a single center. Three hundred and seventy-two consecutive patients who underwent CE for OGIB from June 2002 to January 2012 were enrolled. Follow-up data were obtained from the internal CE database in Renji Hospital (Shanghai, China) and direct phone interviews with the patients or their families. Patients who were lost to follow-up in 12 months after CE were excluded. The Cox ratio hazard model was used to evaluate the risk factors associated with rebleeding, while Kaplan-Meier survival curves and the log-rank test were used to analyze the cumulative rebleeding rates.ResultsThe overall rebleeding rate after CE was 28.6% (97/339) during a median follow-up of 48 months (range: 12-112 months). Multivariate analysis showed that age ≥ 60 years (HR2.473; 95% confidence interval [CI] 1.576-3.881;P=0.000), CE positive findings (HR3.393, 95%CI 1.931-5.963; P=0.000), hemoglobin levels ≤7g/dL before CE (HR2.010, 95%CI 1.261-3.206; P=0.003), non-specific treatments (HR2.500, 95%CI 1.625-3.848; P=0.000) and anticoagulants, antiplatelet or NSAIDs use after CE (HR2.851, 95%CI 1.433-5.674; P=0.003) were independent risk factors associated with rebleeding. Univariate analysis showed that chronic hepatitis was independently associated with rebleeding in CE negative patients (P=0.021).ConclusionsCE has a significant impact on the long-term outcome of patients with OGIB. Further investigation and close follow-up in patients with OGIB and CE negative patients is necessary.
    Journal of Digestive Diseases 12/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: AimFew studies have been performed to test the effect of intestinal electrical stimulation (IES) on intestinal dysmotility. This study aimed to investigate the small intestine transit (SIT) in a canine model of intestinal hypermotility when applying IES.Methods Six female hound dogs were surgically prepared with two chronic intestinal fistulas. The proximal pair of the intestinal serosal electrodes was used for serosal IES and one pair of 28-gauge cardiac pacing wires was attached to the tip of a manometric catheter for mucosal IES. Nitrogen oxide synthase inhibitor, LNNA (N-omega-nitro-L-Arginine) was used to induce hypertensive intestinal motility. SIT was measured during IES. The study consisted of four randomized sessions: session 1(LNNA session), session 2 (LNNA plus serosal IES), session 3 (LNNA plus mucosal IES) and session 4 (control session).ResultsThe intestine transit was slowed down from 31.7±6.1 minutes in the control session to 49.0±6.2 minutes after using LNNA (P=0.003). Both mucosal and serosal IES accelerated SIT compared with the LNNA session. The SIT time was reduced to 17.7±3.4 min in the mucosal IES session (P=0.006, vs control) and 27.5±6.3 minutes in the serosal IES session (P=0.020, vs control). No difference was noted regarding the SIT time between mucosal and serosal IES (P=0.128).Conclusions The electrical stimulation of small intestine significantly accelerates delayed SIT in a hypermotility model and intraluminal stimulation is as effective as serosal one for IES, suggesting IES may have a therapeutic potential for improving intestinal motility.
    Journal of Digestive Diseases 12/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background and AimsIncidence of inflammatory bowel disease (IBD), including Ulcerative Colitis (UC) and Crohn′s disease (CD), is increasing. Imaging techniques are accurate and reliable in diagnosing IBD. The main disadvantage of CT compared with MRI is radiation exposure and the potential risk factor for cancer, especially since IBD patients are already at increased risk of malignancies. High cumulative effective dose (CED) presents in 7–11% of IBD patients. Our aim was to quantify and characterize effective radiation exposure of IBD patients.Methodsretrospective study, from a cohort of IBD patients enrolled in a registry of Clínica las Condes between years 2011-2013. High cumulative radiation exposure was defined as CED > 50 mSv.ResultsA total of 325 IBD patients were enrolled in our registry, including 243 (74.7%) with UC and 82 (25.3%) with CD. High CED was significantly higher in patients with CD compared with UC (19.5% vs 2.4%). Higher exposure to radiation was associated with longer duration of disease, ileal involvement, stricturing behavior, treatments with steroids and biological agents, and CD-related hospitalization or surgery. Abdominopelvic CT and Enteroclysis CT accounted for 93.6% of total CED.ConclusionsA high percentage of IBD patients is exposed to high CED. Radiation-free cross-sectional exams, such as MRI, should be used, especially in young patients, those who have undergone prior surgery and those with severe IBD.
    Journal of Digestive Diseases 11/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: AimsCerebral venous thrombosis (CVT) is a rare but devastating complication of inflammatory bowel disease (IBD) that is estimated to occur in 1.3-6.4% of patients.MethodsA retrospective chart review was performed from April 2009 through May 2014 to identify IBD patients who had CVT diagnosed during their lifetime.ResultsSix IBD patients with cerebral venous thrombosis were identified. The patients presented with hours to days of headache and were found to have venous thrombosis. Four of the six patients had ulcerative colitis and two had Crohn's disease. All six patients were treated with therapeutic anticoagulation. There were two deaths; one patient became comatose and died despite anticoagulation while the other recovered well from the sinus thrombosis but died after a bowel perforation three weeks later.Conclusion This case series demonstrates the critical need for early recognition of neurologic symptoms in patients with IBD during disease flares. It is important to recognize the clinical signs in order to start anticoagulation expeditiously and improve neurological outcomes.
    Journal of Digestive Diseases 11/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE Ecabet sodium is a new non-systemic anti-ulcer agent belonging to the category of gastroprotective agents. In this study we aimed to compare the efficacy of a combination therapy with lansoprazole followed by ecabet sodium with lansoprazole alone in treating endoscopic submucosal dissection (ESD)-induced iatrogenic gastric ulcers.METHODS Ninety patients diagnosed with gastric adenoma or early gastric cancer were randomly divided to either the LS (lansoprazole 30 mg once daily for 4 weeks; n = 45) or the LS + ES (lansoprazole 30 mg once daily for one week followed by ecabet sodium 1500 mg twice daily for 3 weeks; n = 45) groups. Four weeks after threa therapy, follow-up endoscopy was conducted to evaluate the ulcer reduction proportions and ulcer stages between the two groups.RESULTSSeventy-nine patients were included in the final analyses. Both treatment modalities were well-tolerated in most patients with a drug compliance of over 80%. There were no significant differences between the two groups in terms of the ulcer reduction proportions (0.9503 ± 0.1215 in the LS group vs 0.9192 ± 0.0700 in the LS + ES group, P = 0.169) or ulcer stage (P = 0.446). And the prevalences of adverse events related to drugs and bleeding were also similar between the two groups.CONCLUSION Sequential therapy with lansoprazole and ecabet sodium is as effective as lansoprazole alone against ESD-induced gastric ulcers.
    Journal of Digestive Diseases 11/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective Superficial colorectal tumors can be treated effectively by endoscopic submucosal dissection (ESD). Few data are available concerning ESD for residual or recurrent tumors after first endoscopic resection. This study was aimed to evaluate the efficacy of ESD for these lesions.Methods Twenty-eight patients with residual or recurrent colorectal superficial tumors were referred at the Kobe University Hospital for ESD. The therapeutic outcomes and the possible factors predictive of procedure difficulties for ESD were analyzed.ResultsIn total, 27/28 lesions (96%) were successfully treated. There was no related immediate complication. One patient had a delayed perforation treated surgically. En bloc R0 resection was possible in all the patients and curative resection in 26/28 patients (92.8%). One invasive cancer was treated surgically. More than one previous endoscopic resection was the only significant predictive factor for the ESD difficulty. None of the patients experienced recurrence after 22 months (range 3-41) follow-up.Conclusions This study showed that ESD allowed a high rate of en bloc resection for residual or locally recurrent colorectal tumors. Furthermore, these lesions should be treated by ESD as the first-line treatment.
    Journal of Digestive Diseases 11/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective To evaluate risk factors and clinical outcomes for spontaneous rupture of pyogenic liver abscess.MethodsA total of 602 patients diagnosed with pyogenic liver abscess between January 2004 and July 2013 were retrospectively analyzed. Among the 602 patients, 23 patients experienced spontaneous rupture of pyogenic liver abscess.ResultsThe prevalence of spontaneous rupture of pyogenic liver abscess was 3.8%. In multivariate analysis, underlying liver cirrhosis (OR 4.65, P = 0.009), gas forming abscess (OR 3.65, P = 0.026), abscess size (≥6 cm) (OR 10.99, P = 0.002), and other septic metastasis (OR 1.71, P = 0.047) were risk factors for spontaneous rupture of pyogenic liver abscess. Regarding the site of rupture, 20 patients (87%) had localized rupture, specifically, sub-phrenic abscess 3 patients (13%), peri-hepatic abscess 10 patients (43.5%), localized peritoneal abscess 3 patients (13%) and empyema 4 patients (17.4%); and 3 patients (13%) had peritonitis. Ruptures resulting in peritonitis require urgent surgery, whereas localized rupture can be managed with percutaneous drainage in addition to appropriate antibiotics. The mortality rate of spontaneous rupture of pyogenic liver abscess was 4.3%.Conclusions Patients with cirrhosis, abscess size (≥6 cm), gas forming abscess, and other septic metastasis who have pyogenic liver abscess should be monitored closely and may need early intervention for spontaneous rupture of liver abscess.
    Journal of Digestive Diseases 11/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE We aimed to evaluate the efficacy of liver stiffness measurement (LSM) in predicting the presence and severity of esophgeal varices (EV) and its association with liver function in patients with liver cirrhosis.METHODS Medical records of 90 cirrhotic patients who underwent LSM by transient elastography were retrospectively reviewed. The relationship between LSM and the presence and severity of EV were evaluated by esophagogastroduodenoscopy (EGD) and multislice spiral computed tomography (CT). Another 25 healthy individuals were also included.RESULTSLSM was significantly associated with the grading of Child-Pugh score in cirrhotic patients, with the highest LSM in those at Child-Pugh C. Morever, patients with clinically decompensated cirrhosis had higher LSM than those with compensated cirrhosis (36.75 ± 16.54 kPa vs 17.65 ±10.87 kPa, P < 0.01). However, there was no significant difference in LSM value between patients with severe EV and those having no or non-severe EV determined by endoscopy (31.00 ± 18.44 kPa vs 28.18 ± 17.44 kPa) and multislice spiral CT (29.71 ± 18.39 kPa vs 24.90 ± 14.80 kPa), respectively. The diagnostic value of LSM for predicting severe EV was low in unselected cirrhotic patients. The presence of EV examined by EGD and multislice spiral CT was similar to each other.CONCLUSIONSLSM could serve to evaluate continuously the disease progression. However, its role in assessing the EV grades in advanced cirrhosis needs further confirmation. Multislice spiral CT can assess EV accurately and serve as an alternative to endoscopy in the assessment of portal hypertension.
    Journal of Digestive Diseases 11/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ulcerative colitis (UC) and Crohn's disease (CD) are the two major types of inflammatory bowel disease (IBD). Despite intensive study, it is still challenging because the precise aetiology and pathogenesis remains unclear. Studies showed IBD is associated with changes in the composition of intestinal microbiota, either as a cause or consequence of abnormal host immune response in genetic susceptible population. Two specific microorganisms (Mycobacterium avium subspecies paratuberculosis and E. coli) get more widely studied, but till now no single microorganism has been identified as the only pathogen. Genetic susceptibility data also suggest impaired handling of bacteria as well as an improper immune response to potential pathogens. The microbiota also provides new therapeutic methods. Fecal microbiota transplantation (FMT) may restore the balance of intestinal flora to supplement or optimize current therapies.
    Journal of Digestive Diseases 11/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: AIMCurrent guidelines for treating early gastric cancer (EGC) with endoscopic submucosal dissection (ESD) are in evolution, with broader indication criteria. This systematic review was to assess the application of expanded indication (EI) by comparing the outcomes between the conventional indication (CI) group and the EI group.METHODS Literature databases were searched. Short-term outcomes including endoscopic resection, complications and local recurrence, and long-term outcomes including gastric cancer-specific survival rate and overall survival rate were compared between the two groups. Meta-analysis was conducted using Review Manager 5.2.RESULTSTotally, 13 studies were identified and 11298 patients with 11627 EGC lesions were evaluated. The EI group had lower rates of en bloc resection (93.6% vs 97.0%, P < 0.01), complete resection (87.8% vs 95.8%, P < 0.01) and curative resection (82.4% vs 94.0%, P < 0.01) than the CI group. The rates of delayed bleeding and perforation were both significantly higher in the EI group (3.9% vs 2.8%, P = 0.04 and 3.9% vs 1.8%, P < 0.01). Local recurrence rates were 0.6% in the CI group and 1.5% in the EI group (P = 0.03). But there were no significant differences between the two groups in gastric-cancer specific survival rate (P = 0.22) and overall survival rate (P = 0.96).CONCLUSIONS Long-term survival rates in the EI group did not differ from that in the CI group, although the EI group was associated with more unfavorable short-term outcomes. Thus, ESD could be recommended as an effective therapy for EGCs of EI.
    Journal of Digestive Diseases 11/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective To determine the long-term outcome after endoscopic submucosal dissection (ESD) in early gastric cancer (EGC) patients, we analyzed the results and the clinical outcomes after ESD of EGC according to the pathologic extent.MethodsESDs were performed in 309 EGCs of 280 patients. They were classified by pathological severity based on absolute indication (AI), expanded indication (EI) or beyond expanded indication (BEI). The therapeutic outcomes were compared among the three groups.ResultsThe complete resection rates were 96.4% in the AI-EGCs, 78.7% in the EI-EGCs, and 41.2% in the BEI-EGCs (P = 0.000). The en bloc resection rates were 97.6% in the AI-EGCs, 87.4% in the EI-EGCs, and 86.3% in the BEI-EGCs (P = 0.023). The 5-year tumor recurrence rates were 1.8% in the AI-group, 1.5% in the EI-group and 15.4% in the BEI-group (P = 0.000). The 5-year disease-specific survival rates were 100% in the AI-group, 100% in the EI-group, and 97.4% in the BEI-group (P = 0.088). The 5-year disease-free survival rates were 98.2% in the AI-group, 98.5% in the EI-group, and 84.6% in the BEI-group (P = 0.000).ConclusionsESD was effective and safe in the AI or EI-EGCs but a comparatively high rate of recurrence resulted from ESD in the BEI-EGCs. However, the long-term outcome of BEI-EGCs that did not receive additional surgery was better compared with the natural course of EGCs. Thus, ESD may be considered in specific BEI-EGCs patients at high-risk for surgery.
    Journal of Digestive Diseases 11/2014;
  • Journal of Digestive Diseases 11/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pancreatic acinar cell necrosis and subsequent inflammatory response aggravate acute pancreatitis (AP), its underlying mechanism has not been fully elucidated. The tetraspanin CD9 was reported to mediate inflammatory signaling through regulating molecular organization at cell surface. This study aimed to investigate the role of CD9 during caerulein-induced experimental AP in mice.
    Journal of Digestive Diseases 10/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective This study aimed to investigate the association of interleukin 28B (IL28B) single nucleotide polymorphisms (SNPs) with sustained response (SVR) in Chinese Han patients with chronic hepatitis C (CHC) and to analysz the correlations between IL28B SNPs and their demographic, virological and clinical characteristics.Methods Altogether 631 Chinese Han individuals including 297 CHC patients treated with pegylated interferon α plus ribavirin, 14 spontaneous hepatitis C virus (HCV) responders and 320 healthy controls were enrolled in the study. Two main SNPs of IL28B, rs12979860 and rs8099917, were genotyped using SNaPshot Multiplex assay. Associations between IL28B and treatment outcomes as well as demographic, virological and clinical characteristics of the patients were assessed by multivariate logistic regression.ResultsThe proportion of individuals with rs12979860 CC genotype or rs8099917 TT genotype was similar in healthy controls and CHC patients, although all spontaneous responders presented with these two genotypes. Patients with IL28B genotypes had a significantly high rate of rapid virological response (RVR) and SVR. Multivariate analysis revealed that IL28B SNP rs12979860 CC genotype (odds ratio [OR] 14.986, 95% confidence interval (CI) 5.056–44.422, P < 0.001), age <40 years (OR 0.239, 95% CI 0.600–0.954, P = 0.043) and non-G1 genotype (OR 0.122, 95% CI 0.015–0.985, P = 0.048) were independent predictors for SVR. And rs12979860 CC genotype (OR 25.754, 95% CI 3.315–200.101, P = 0.002) and rs8099917 TT genotype (OR 15.740, 95% CI 2.101–118.07, P < 0.001) were the predictors for RVR. rs12979860 CC genotype and rs8099917 TT genotype were more prevalent in patients with non-G1 genotype than those with G1 genotype.ConclusionsIL-28B rs12979860 CC genotype is a significant predictor for SVR and RVR in Chinese Han patients with CHC. Non-G1 HCV genotype is associated with favorable IL28B genotypes.
    Journal of Digestive Diseases 10/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective Emerging evidences have shown that MiR-146a rs2910164 polymorphism might be associated with susceptibility to colorectal cancer. However, previous published studies failed to achieve a comprehensive conclusion. To address this issue, an updated meta-analysis was performed.MethodsA comprehensive electronic search was conducted in the following resources: PubMed, Embase,China BioMedicine (CBM),the Cochrane Library, and Google Scholar for eligible studies. Odds ratio (OR) and corresponding 95% confidence interval (CI) was used in the quantitative synthesis.ResultsThe database search identified 93 eligible studies, of which seven (comprising 2978 cases and 3576 controls) were included. The results indicate that there is no association between miR-146a rs2910164 polymorphism and colorectal cancer risk neither in the overall analysis nor among Asians when stratified on the basis of ethnicity.Conclusion The current study revealed that miR-146a G/C genetic polymorphism was not related to susceptibility to colorectal cancer.
    Journal of Digestive Diseases 10/2014;
  • Journal of Digestive Diseases 10/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Inflammatory bowel diseases (IBD) are chronic diseases of unknown etiology, in which genetic factors contribute to the pathogenesis. The cornerstone of conventional treatment is glucocorticoid (GCs) whose sensitivity varies from patient to patient. Genes such as Multidrug resistance 1 (MDR1), NACHT leucine-rich-repeat protein 1 (NALP1), Glucocorticoid receptor (GR) and its co-chaperone FKBP5 participate in the anti-inflammatory mechanism of GCs. Variations of these genes are related to GCs response, and MDR1 polymorphisms are also associated with the susceptibility to IBD in Caucasians. However, whether similar relationships exist in Chinese population remains unclear. Thus, the aims of this research were to investigate the polymorphisms of these genes influence the response to GCs in Chinese IBD patients and the relationships between MDR1 and IBD susceptibility.Methods8 Single-nucleotide polymorphisms (SNPs) were selected and genotyped in 156 IBD patients treated with GCs and 223 healthy controls by MALDI-TOF MS assay. Patients were defined as GCs responders, dependants or resistants after one year follow up.ResultsThe CC genotypes of rs1128503 and rs1045642 in MDR1 gene were more frequent in GC dependants compared with the responsive patients of Crohn's Disease (CD) (OR 6.583, 95%CI 1.760-24.628, P=0.019 and OR 3.873, 95%CI 1.578-9.506, P=0.009, respectively). The G allele of MDR1 rs2032582 was less frequent among CD cases than in controls (OR 0.668, 95%CI 0.484-0.921, P=0.014). G allele carriers were also less likely to develop non-stricturing and non-penetrating CD (OR 0.661, 95% CI 0.462-0. 946, P=0.023) and ileocolonic CD (OR 0.669, 95%CI 0.472-0.948, P=0.024). There was no significant finding in Ulcerative Colitis ( UC).Conclusion Polymorphisms of MDR1 associated with GCs response and the predisposition to CD in Chinese population. More studies are needed to elucidate the functions of MDR1 polymorphisms in IBD and their role as genetic markers for GCs response.
    Journal of Digestive Diseases 10/2014;